258 related articles for article (PubMed ID: 27246829)
41. ICOSL Stimulation by ICOS-Fc Accelerates Cutaneous Wound Healing In Vivo.
Stoppa I; Gigliotti CL; Clemente N; Pantham D; Dianzani C; Monge C; Puricelli C; Rolla R; Sutti S; Renò F; Boldorini R; Boggio E; Dianzani U
Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806368
[TBL] [Abstract][Full Text] [Related]
42. The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy.
Fu T; He Q; Sharma P
Cancer Res; 2011 Aug; 71(16):5445-54. PubMed ID: 21708958
[TBL] [Abstract][Full Text] [Related]
43. Isolation strategies of regulatory T cells for clinical trials: phenotype, function, stability, and expansion capacity.
Ukena SN; Höpting M; Velaga S; Ivanyi P; Grosse J; Baron U; Ganser A; Franzke A
Exp Hematol; 2011 Dec; 39(12):1152-60. PubMed ID: 21864487
[TBL] [Abstract][Full Text] [Related]
44. First-in-class small molecule inhibitors of ICOS/ICOSL interaction as a novel class of immunomodulators.
Abdel-Rahman SA; Świderek K; Gabr MT
RSC Med Chem; 2023 Sep; 14(9):1767-1777. PubMed ID: 37731692
[TBL] [Abstract][Full Text] [Related]
45. Increase in activated Treg in TIL in lung cancer and in vitro depletion of Treg by ADCC using an antihuman CCR4 mAb (KM2760).
Kurose K; Ohue Y; Sato E; Yamauchi A; Eikawa S; Isobe M; Nishio Y; Uenaka A; Oka M; Nakayama E
J Thorac Oncol; 2015 Jan; 10(1):74-83. PubMed ID: 25325779
[TBL] [Abstract][Full Text] [Related]
46. ICOS is required for the generation of both central and effector CD4(+) memory T-cell populations following acute bacterial infection.
Marriott CL; Carlesso G; Herbst R; Withers DR
Eur J Immunol; 2015 Jun; 45(6):1706-15. PubMed ID: 25754933
[TBL] [Abstract][Full Text] [Related]
47. CXCR5 and ICOS expression identifies a CD8 T-cell subset with T
Le KS; Amé-Thomas P; Tarte K; Gondois-Rey F; Granjeaud S; Orlanducci F; Foucher ED; Broussais F; Bouabdallah R; Fest T; Leroux D; Yadavilli S; Mayes PA; Xerri L; Olive D
Blood Adv; 2018 Aug; 2(15):1889-1900. PubMed ID: 30087107
[TBL] [Abstract][Full Text] [Related]
48. Downregulation of myeloma-induced ICOS-L and regulatory T cell generation by lenalidomide and dexamethasone therapy.
Scott GB; Carter C; Parrish C; Wood PM; Cook G
Cell Immunol; 2015 Sep; 297(1):1-9. PubMed ID: 26051632
[TBL] [Abstract][Full Text] [Related]
49. Immunotherapy of experimental melanoma with ICOS-Fc loaded in biocompatible and biodegradable nanoparticles.
Clemente N; Boggio E; Gigliotti LC; Raineri D; Ferrara B; Miglio G; Argenziano M; Chiocchetti A; Cappellano G; Trotta F; Caldera F; Capucchio MT; Yagi J; Rojo MJ; Renò F; Cavalli R; Dianzani C; Dianzani U
J Control Release; 2020 Apr; 320():112-124. PubMed ID: 31962094
[TBL] [Abstract][Full Text] [Related]
50. ICOS-Fc as innovative immunomodulatory approach to counteract inflammation and organ injury in sepsis.
Alves GF; Stoppa I; Aimaretti E; Monge C; Mastrocola R; Porchietto E; Einaudi G; Collotta D; Bertocchi I; Boggio E; Gigliotti CL; Clemente N; Aragno M; Fernandes D; Cifani C; Thiemermann C; Dianzani C; Dianzani U; Collino M
Front Immunol; 2022; 13():992614. PubMed ID: 36119089
[TBL] [Abstract][Full Text] [Related]
51. The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy.
Solinas C; Gu-Trantien C; Willard-Gallo K
ESMO Open; 2020 Jan; 5(1):. PubMed ID: 32516116
[TBL] [Abstract][Full Text] [Related]
52. Immunomodulation of inducible co-stimulator (ICOS) in human cytokine-induced killer cells against cholangiocarcinoma through ICOS/ICOS ligand interaction.
He M; Wang Y; Shi WJ; Wang SJ; Sha HF; Feng JX; Wang J
J Dig Dis; 2011 Oct; 12(5):393-400. PubMed ID: 21955433
[TBL] [Abstract][Full Text] [Related]
53. Clinical significance of T-regulatory cells in B-cell non-Hodgkin's lymphoma.
Baraka A; Salem HM
Egypt J Immunol; 2011; 18(2):23-30. PubMed ID: 23082467
[TBL] [Abstract][Full Text] [Related]
54. Pulmonary sarcoidosis is associated with high-level inducible co-stimulator (ICOS) expression on lung regulatory T cells--possible implications for the ICOS/ICOS-ligand axis in disease course and resolution.
Sakthivel P; Grunewald J; Eklund A; Bruder D; Wahlström J
Clin Exp Immunol; 2016 Feb; 183(2):294-306. PubMed ID: 26415669
[TBL] [Abstract][Full Text] [Related]
55. Human regulatory T cells suppress proliferation of B lymphoma cells.
Grygorowicz MA; Biernacka M; Bujko M; Nowak E; Rymkiewicz G; Paszkiewicz-Kozik E; Borycka IS; Bystydzienski Z; Walewski J; Markowicz S
Leuk Lymphoma; 2016 Aug; 57(8):1903-20. PubMed ID: 26758248
[TBL] [Abstract][Full Text] [Related]
56. Role of plasmacytoid dendritic cells and inducible costimulator-positive regulatory T cells in the immunosuppression microenvironment of gastric cancer.
Huang XM; Liu XS; Lin XK; Yu H; Sun JY; Liu XK; Chen C; Jin HL; Zhang GE; Shi XX; Zhang Q; Yu JR
Cancer Sci; 2014 Feb; 105(2):150-8. PubMed ID: 24261990
[TBL] [Abstract][Full Text] [Related]
57. Association of polymorphisms in the ICOS and ICOSL genes with the pathogenesis of autoimmune thyroid diseases.
Yoshie N; Watanabe M; Inoue N; Kawaguchi H; Hidaka Y; Iwatani Y
Endocr J; 2016; 63(1):61-8. PubMed ID: 26560438
[TBL] [Abstract][Full Text] [Related]
58. Aberrant ICOS
Kälble F; Mai C; Wagner M; Schober L; Schaier M; Zeier M; Spratte J; Fluhr H; Steinborn A
Am J Reprod Immunol; 2016 Nov; 76(5):415-425. PubMed ID: 27650411
[TBL] [Abstract][Full Text] [Related]
59. Human thymus medullary epithelial cells promote regulatory T-cell generation by stimulating interleukin-2 production via ICOS ligand.
Nazzal D; Gradolatto A; Truffault F; Bismuth J; Berrih-Aknin S
Cell Death Dis; 2014 Sep; 5(9):e1420. PubMed ID: 25210803
[TBL] [Abstract][Full Text] [Related]
60. CD4⁺Foxp3⁺ Treg and its ICOS⁺ subsets in patients with myocardial infarction.
Ghourbani Gazar S; Andalib A; Hashemi M; Rezaei A
Iran J Immunol; 2012 Mar; 9(1):53-60. PubMed ID: 22426168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
